RETRACTED: Curcumin inhibits esophageal squamous cell carcinoma progression through down‐regulating the circNRIP1 / miR ‐532‐3p/ AKT pathway
Environmental Toxicology · 2023
DOI: 10.1002/tox.23905 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Environmental Toxicology, 2023. Verfasst von Tianxia Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Curcumin, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Doctoral Scientific Research of Henan University of Chinese Medicine, the Science and Technology Project of Henan Province, The Medical Science Research Project of Henan Province.
Abstract (Originalsprache)
Curcumin shows an anti‐cancer role in many kinds of tumors. However, the mechanism of its anti‐tumor function in esophageal squamous cell carcinoma (ESCC) remains largely unknown. Herein, we explored the therapeutic potential of curcumin for esophageal cancer. Curcumin could time‐ and dose‐dependently inhibit ESCC cells activity. Additionally, ESCC cells exposed to 20 μM of curcumin exhibited significantly decreased proliferative and invasive capacities, as well as enhanced cell apoptosis. ESCC tissues and cells exhibited significantly increased circNRIP1 expression when compared to their counterparts. circNRIP1 knockdown markedly impaired cell proliferation, clone formation, cell migration and invasion but promoted apoptosis. Exposure to 10–20 μM of curcumin inhibited circNRIP1 expression, however, overexpression of circNRIP1 could significantly restored the biological characteristics that were inhibited by curcumin exposure in vivo and in vitro. circNRIP1 promoted the malignancy of ESCC by combining miR‐532‐3p, and downstream AKT3. Curcumin inhibited AKT phosphorylation by up‐regulating miR‐532‐3p expression, thereby inhibiting the activation of the AKT pathway. In summary, curcumin is a potent inhibitor of ESCC growth, which can be achieved through the regulation of the circNRIP1/miR‐532‐3p/AKT pathway. This research may provide new mechanisms for curcumin to inhibit the malignant development of ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
- Trauma Research Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
- Translational Medical Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
- Department of Clinical Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Hongya Guan, Yueli Zhang
Förderung
- Doctoral Scientific Research of Henan University of Chinese Medicine
- the Science and Technology Project of Henan Province
- The Medical Science Research Project of Henan Province
- The Key research Project of higher education institutions in Henan Province
Zitieren
APA
Luo, T., Guan, H., Liu, J., Wang, J., & Zhang, Y. (2023). RETRACTED: Curcumin inhibits esophageal squamous cell carcinoma progression through down‐regulating the circNRIP1 / miR ‐532‐3p/ AKT pathway. Environmental Toxicology. https://doi.org/10.1002/tox.23905
Vancouver
Luo T, Guan H, Liu J, Wang J, Zhang Y. RETRACTED: Curcumin inhibits esophageal squamous cell carcinoma progression through down‐regulating the circNRIP1 / miR ‐532‐3p/ AKT pathway. Environmental Toxicology. 2023. doi:10.1002/tox.23905
BibTeX
@article{Luo2023,
author = {Luo, Tianxia and Guan, Hongya and Liu, Jia and Wang, Jiang and Zhang, Yueli},
title = {RETRACTED: Curcumin inhibits esophageal squamous cell carcinoma progression through down‐regulating the circNRIP1 / miR ‐532‐3p/ AKT pathway},
journal = {Environmental Toxicology},
year = {2023},
doi = {10.1002/tox.23905}
}
EUVIMED